Survival probabilities
| . | At diagnosis, no. . | After 2 y . | After 5 y . | After 8 y . | After 10 y . | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | No. . | % (95% CI) . | No. . | % (95% CI) . | No. . | % (95% CI) . | ||
| Group 1: eligible for HSCT and related donor available | |||||||||
| Total | 135 | 103 | 76 (68-83) | 84 | 62 (53-70) | 62 | 56 (48-64) | 23 | 53 (44-61) |
| Low risk | 85 | 66 | 78 (67-85) | 58 | 68 (57-77) | 45 | 64 (53-74) | 16 | 59 (47-69) |
| Nonlow risk | 50 | 37 | 74 (59-84) | 26 | 52 (37-65) | 17 | 43 (29-56) | 7 | 43 (29-56) |
| Group 2: eligible for HSCT and no related donor available | |||||||||
| Total | 219 | 130‡ | 89 (84-93) | 81 | 73 (64-79) | 43 | 57 (47-65) | 13 | 52 (41-61) |
| Low risk | 129 | 81 | 93 (87-97) | 54 | 85 (75-91) | 30 | 66 (53-77) | 7 | 62 (48-73) |
| Nonlow risk | 90 | 49 | 84 (74-90) | 27 | 56 (42-68) | 13 | 44 (30-57) | 6 | 40 (25-54) |
| Group 3: patients not eligible for HSCT | |||||||||
| Total | 265* | 241 | 91 (87-94) | 152 | 60 (54-66) | 70 | 40 (34-46) | 22 | 32 (25-39) |
| Low risk | 47 | 42 | 91 (79-97) | 24 | 58 (42-71) | 12 | 43 (28-57) | 4 | 32 (16-49) |
| Nonlow risk | 217 | 198 | 91 (87-94) | 128 | 61 (54-67) | 58 | 40 (33-47) | 18 | 32 (24-40) |
| All patients | |||||||||
| Total | 621† | 476 | 87 (84-90) | 317 | 64 (59-67) | 175 | 48 (44-53) | 58 | 42 (37-47) |
| Low risk | 262 | 190 | 87 (82-91) | 136 | 72 (66-78) | 87 | 61 (54-68) | 27 | 55 (47-62) |
| Nonlow risk | 358 | 285 | 87 (83-90) | 181 | 58 (53-63) | 88 | 41 (35-46) | 31 | 35 (29-41) |
| . | At diagnosis, no. . | After 2 y . | After 5 y . | After 8 y . | After 10 y . | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % (95% CI) . | No. . | % (95% CI) . | No. . | % (95% CI) . | No. . | % (95% CI) . | ||
| Group 1: eligible for HSCT and related donor available | |||||||||
| Total | 135 | 103 | 76 (68-83) | 84 | 62 (53-70) | 62 | 56 (48-64) | 23 | 53 (44-61) |
| Low risk | 85 | 66 | 78 (67-85) | 58 | 68 (57-77) | 45 | 64 (53-74) | 16 | 59 (47-69) |
| Nonlow risk | 50 | 37 | 74 (59-84) | 26 | 52 (37-65) | 17 | 43 (29-56) | 7 | 43 (29-56) |
| Group 2: eligible for HSCT and no related donor available | |||||||||
| Total | 219 | 130‡ | 89 (84-93) | 81 | 73 (64-79) | 43 | 57 (47-65) | 13 | 52 (41-61) |
| Low risk | 129 | 81 | 93 (87-97) | 54 | 85 (75-91) | 30 | 66 (53-77) | 7 | 62 (48-73) |
| Nonlow risk | 90 | 49 | 84 (74-90) | 27 | 56 (42-68) | 13 | 44 (30-57) | 6 | 40 (25-54) |
| Group 3: patients not eligible for HSCT | |||||||||
| Total | 265* | 241 | 91 (87-94) | 152 | 60 (54-66) | 70 | 40 (34-46) | 22 | 32 (25-39) |
| Low risk | 47 | 42 | 91 (79-97) | 24 | 58 (42-71) | 12 | 43 (28-57) | 4 | 32 (16-49) |
| Nonlow risk | 217 | 198 | 91 (87-94) | 128 | 61 (54-67) | 58 | 40 (33-47) | 18 | 32 (24-40) |
| All patients | |||||||||
| Total | 621† | 476 | 87 (84-90) | 317 | 64 (59-67) | 175 | 48 (44-53) | 58 | 42 (37-47) |
| Low risk | 262 | 190 | 87 (82-91) | 136 | 72 (66-78) | 87 | 61 (54-68) | 27 | 55 (47-62) |
| Nonlow risk | 358 | 285 | 87 (83-90) | 181 | 58 (53-63) | 88 | 41 (35-46) | 31 | 35 (29-41) |
95% CI indicates 95% confidence interval.
For one patient, the prognostic score was not available.
Additional to groups 1, 2, and 3, 2 patients eligible for HSCT were added for whom information on donor availability was missing.
Between diagnosis and 2 years, reduction in patient number was mainly due to MUD transplantations in first chronic phase.